medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-11-57-61medsovet-1542Research ArticleДЕМИЕЛИНИЗИРУЮЩИЕ ЗАБОЛЕВАНИЯDEMYELINATING DISEASESТЕРИФЛУНОМИД – НОВЫЙ ТАБЛЕТИРОВАННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ РЕМИТИРУЮЩЕГО РАССЕЯННОГО СКЛЕРОЗА (ОБЗОР)TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)ПОПОВАЕ. В.POPOVAE. V.

к.м.н.

PhD in medicine

БОЙКОА. Н.BOYKOA. N.

д.м.н., профессор

MD, Prof.

ДАВЫДОВСКАЯМ. В.DAVYDOVSKAYAM. V.

д.м.н.

MD

ЗОЛОТОВАС. Н.ZOLOTOVAS. N.ХАЧАНОВАН. В.KHACHANOVAN. V.

к.м.н.

PhD

ШАРАНОВАС. Н.SHARANOVAS. N.Межокружное отделение рассеянного склероза на базе Городской клинической больницы №24 Департамента здравоохранения г. Москвы Кафедра неврологии, нейрохирургии и медицинской генетики Российского национального исследовательского медицинского университета им. Н.И. Пирогова, МоскваРоссияInterretional department of disseminated sclerosis on the basis of SBHI Municipal Clinical Hospital No. 24 of Moscow Healthcare Department; Neurology, neurosurgery and medical genetics department of Pirogov Russian National Research Medical UniversityRussian FederationМежокружное отделение рассеянного склероза на базе Городской клинической больницы №24 Департамента здравоохранения г. МосквыРоссияInterretional department of disseminated sclerosis on the basis of SBHI Municipal Clinical Hospital No. 24 of Moscow Healthcare Department;Russian Federation2016301220160115761Copyright © ПОПОВА Е.В., БОЙКО А.Н., ДАВЫДОВСКАЯ М.В., ЗОЛОТОВА С.Н., ХАЧАНОВА Н.В., ШАРАНОВА С.Н., 20162016ПОПОВА Е.В., БОЙКО А.Н., ДАВЫДОВСКАЯ М.В., ЗОЛОТОВА С.Н., ХАЧАНОВА Н.В., ШАРАНОВА С.Н.POPOVA E.V., BOYKO A.N., DAVYDOVSKAYA M.V., ZOLOTOVA S.N., KHACHANOVA N.V., SHARANOVA S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1542

В данном обзоре представлены результаты экспериментальных и клинических исследований нового перорального препарата терифлуномид для патогенетического лечения рассеянного склероза (РС). Приведены механизм действия, данные клинических исследований II и III фаз по клинической эффективности, переносимости и безопасности. Обсуждается место терифлуномида в патогенетическом лечении РС.

This review includes results of experimental and clinical studies of new oral drug teriflunomide for pathogenetic treatment of multiple sclerosis (MS). Given the mechanism of action, clinical data of the studies II and III phases of clinical efficacy, tolerability and safety. Discusses the place of teriflunomide in pathogenetic treatment of MS.

рассеянный склерозтерифлуномидmultiple sclerosisteriflunomideReferencesClaussen MKorn T. Immune mechanisms of new therapeutic strategies in MS – Teriflunomide. Clinical Immunology. 2012;142(1):49-56. doi:10.1016/j.clim.2011.02.011.Claussen MKorn T. Immune mechanisms of new therapeutic strategies in MS – Teriflunomide. Clinical Immunology. 2012;142(1):49-56. doi:10.1016/j.clim.2011.02.011.O’Connor POh. An update of teriflunomide for treatment of multiple sclerosis. Therapeutics and Clinical Risk Management. 2013:177.doi:10.2147/tcrm.s30947.O’Connor POh. An update of teriflunomide for treatment of multiple sclerosis. Therapeutics and Clinical Risk Management. 2013:177.doi:10.2147/tcrm.s30947.Bar-Or A. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Experimental Neurology. 2014;262:57-65. doi:10.1016/j.expneurol.2014.06.005.Bar-Or A. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Experimental Neurology. 2014;262:57-65. doi:10.1016/j.expneurol.2014.06.005.Garnock-Jones K. Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis. CNS Drugs. 2013; 27(12): 1103-1123. doi:10.1007/s40263-013-0118-2.Garnock-Jones K. Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis. CNS Drugs. 2013; 27(12): 1103-1123. doi:10.1007/s40263-013-0118-2.O’Connor P, Li D, Freedman M et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900. doi:10.1212/01.wnl.0000203121.04509.31.O’Connor P, Li D, Freedman M et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900. doi:10.1212/01.wnl.0000203121.04509.31.Confavreux C, Li D, Freedman M et al. Longterm follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis Journal. 2012;18(9):1278-1289. doi:10.1177/1352458512436594.Confavreux C, Li D, Freedman M et al. Longterm follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis Journal. 2012;18(9):1278-1289. doi:10.1177/1352458512436594.O’Connor P, Wolinsky J, Confavreux C et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2011;365(14):1293-1303. doi:10.1056/nejmoa1014656.O’Connor P, Wolinsky J, Confavreux C et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2011;365(14):1293-1303. doi:10.1056/nejmoa1014656.Confavreux C, O’Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(3):247-256. doi:10.1016/s1474-4422(13)70308-9.Confavreux C, O’Connor P, Comi G et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2014;13(3):247-256. doi:10.1016/s1474-4422(13)70308-9.Vermersch P, Czlonkowska A, Grimaldi L et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 2013;20(6):705-716. doi:10.1177/1352458513507821.Vermersch P, Czlonkowska A, Grimaldi L et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 2013;20(6):705-716. doi:10.1177/1352458513507821.Comi G, Freedman M, Kappos L et al. Pooled safety and tolerability data from four placebocontrolled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders. 2016;5:97-104. doi:10.1016/j.msard.2015.11.006.Comi G, Freedman M, Kappos L et al. Pooled safety and tolerability data from four placebocontrolled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders. 2016;5:97-104. doi:10.1016/j.msard.2015.11.006.HARRISON SBERGFELD W. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine. 2009;76(6):361-367. doi:10.3949/ccjm.76a.08080.HARRISON SBERGFELD W. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine. 2009;76(6):361-367. doi:10.3949/ccjm.76a.08080.Freedman M. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Therapeutic Advances in Chronic Disease. 2013;4(5):192-205. doi:10.1177/2040622313492810.Freedman M. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Therapeutic Advances in Chronic Disease. 2013;4(5):192-205. doi:10.1177/2040622313492810.Dörr JPaul F. The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Curr Treat Options Neurol. 2015;17(6). doi:10.1007/s11940-015-0354-5.Dörr JPaul F. The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Curr Treat Options Neurol. 2015;17(6). doi:10.1007/s11940-015-0354-5.Kieseier Benamor M. Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing– Remitting Multiple Sclerosis. Neurology and Therapy. 2014;3(2):133-138. doi:10.1007/s40120-014-0020-y.Kieseier Benamor M. Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing– Remitting Multiple Sclerosis. Neurology and Therapy. 2014;3(2):133-138. doi:10.1007/s40120-014-0020-y.Utz K, Hoog J, Wentrup A et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Therapeutic Advances in Neurological Disorders. 2014;7(6):263-275. doi:10.1177/1756285614555335.Utz K, Hoog J, Wentrup A et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Therapeutic Advances in Neurological Disorders. 2014;7(6):263-275. doi:10.1177/1756285614555335.Calabrese, M. et al., 2009. Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis. Arch Neurol, 66(9), pp.1144–1150.Calabrese, M. et al., 2009. Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis. Arch Neurol, 66(9), pp.1144–1150.Comi, G. et al., 2016. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 5, pp.97–104.Comi, G. et al., 2016. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders, 5, pp.97–104.Confavreux, C. et al., 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebocontrolled, phase 3 trial. The Lancet Neurology, 13(3), pp.247–256.Confavreux, C. et al., 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebocontrolled, phase 3 trial. The Lancet Neurology, 13(3), pp.247–256.Harrison, S. & Bergfeld, W., 2009. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine, 76(6), pp.361–367.Harrison, S. & Bergfeld, W., 2009. Diffuse hair loss: Its triggers and management. Cleveland Clinic Journal of Medicine, 76(6), pp.361–367.Kieseier, B.C. & Benamor, M., 2014. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurology and therapy, 3(2), pp.133–138.Kieseier, B.C. & Benamor, M., 2014. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurology and therapy, 3(2), pp.133–138.Knecht, W. et al., 1996. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. European journal of biochemistry / FEBS, 240(1), pp.292–301. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8925840.Knecht, W. et al., 1996. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. European journal of biochemistry / FEBS, 240(1), pp.292–301. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8925840.O ’connor, P. et al., 2011. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. Chilly Mazarin (H.B., P.T.) – both in France Stockholm (T.P.O.); Sanofi-Aventis N Engl J Med, 14365(6), pp.1293–303.O ’connor, P. et al., 2011. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. Chilly Mazarin (H.B., P.T.) – both in France Stockholm (T.P.O.); Sanofi-Aventis N Engl J Med, 14365(6), pp.1293–303.Popescu, V. et al., 2013. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry, 84(10), pp.1082–1091. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23524331.Popescu, V. et al., 2013. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry, 84(10), pp.1082–1091. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23524331.Riley, C. et al., 2012. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert review of neurotherapeutics, 12(3), pp.323–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22364331.Riley, C. et al., 2012. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert review of neurotherapeutics, 12(3), pp.323–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22364331.Sartori, A., Carle, D. & Freedman, M.S., 2014. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 15(7), pp.1019–1027. Available at: http://informahealthcare.com/doi/abs/10.1517/14656566.2014.902936n http://informahealthcare.com/doi/pdf/10.1517/14656566.2014.902936.Sartori, A., Carle, D. & Freedman, M.S., 2014. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 15(7), pp.1019–1027. Available at: http://informahealthcare.com/doi/abs/10.1517/14656566.2014.902936n http://informahealthcare.com/doi/pdf/10.1517/14656566.2014.902936.Sormani, M.P., Arnold, D.L. & De Stefano, N., 2014. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 75(1), pp.43–49.Sormani, M.P., Arnold, D.L. & De Stefano, N., 2014. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 75(1), pp.43–49.De Stefano, N. et al., 2014. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs, 28(2), pp.147–156.De Stefano, N. et al., 2014. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs, 28(2), pp.147–156.Treadaway, K. et al., 2009. Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 256(4), pp.568–576.Treadaway, K. et al., 2009. Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology, 256(4), pp.568–576.Ullrich, A. et al., 2001. Recombinant expression of n-terminal truncated mutants of the membrane bound mouse, rat and human fl avoenzyme dihydroorotate dehydrogenase: A versatile tool to rate inhibitor eff ects? European Journal of Biochemistry, 268(6), pp.1861–1868. atology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007; 56(9):2896-2904.Ullrich, A. et al., 2001. Recombinant expression of n-terminal truncated mutants of the membrane bound mouse, rat and human fl avoenzyme dihydroorotate dehydrogenase: A versatile tool to rate inhibitor eff ects? European Journal of Biochemistry, 268(6), pp.1861–1868. atology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007; 56(9):2896-2904.

The authors declare that there are no conflicts of interest present.